FDA gives green light to trial of HBV treatment GIGA-2339
The U.S. Food and Drug Administration (FDA) has given Gigagen the go-ahead to start clinical testing of GIGA-2339, its experimental treatment for hepatitis B…
Marisa Wexler, MS, Senior Science Writer — 
Articles by Marisa Wexler
PFIC treatment IN016 gets FDA orphan drug status
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IN016, an experimental therapy Innorna is developing for progressive familial…
Pemvidutide seen to lower liver fat in MASLD patients in Phase 1 trial
Pemvidutide, Altimmune’s experimental therapy, significantly reduced liver fat and inflammation, as well as body weight, among overweight or obese people with metabolic dysfunction-associated…
NGM Bio raises funds to launch clinical trial of aldafermin for PSC
NGM Biopharmaceuticals has raised $122 million in financing, which the California-based company will use to help launch a planned registrational clinical trial to test…
American Liver Foundation aiming to improve care for patients
The American Liver Foundation (ALF) has launched two projects that aim to improve care for people with metabolic dysfunction-associated steatotic liver disease (MASLD)…
PSC treatment bexotegrast safe, eases liver scarring in early trial
Six months of treatment with a high dose of bexotegrast, Pliant Therapeutics’ oral candidate, was superior to a placebo at reducing markers of disease…
Facial temperature patterns could help detect MASLD: Study
Metabolic dysfunction-associated steatotic liver disease (MASLD), a form of fatty liver disease, and other aging-related metabolic disorders may be detectable using computer-based analyses of…
EU initiative aims to improve early detection of rare genetic diseases
An initiative in the European Union (EU) aims to speed up the diagnosis of rare genetic disorders such as Alagille syndrome in newborns using…
Global Fatty Liver Day to raise awareness of ‘concealed epidemic’
Global Fatty Liver Day, this year falling on June 13, is an annual effort to raise awareness about metabolic dysfunction-associated steatotic liver disease…
Seladelpar still eases itch, liver damage after 2 years: PBC trial
Two years of treatment with seladelpar, Gilead Sciences’ oral candidate, safely results in rapid and sustained reductions in itching and liver damage markers for…